Clinical Trials in Chalon-sur-Saône, France
15 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Histopathological Analysis of Renal Biopsies With Dynamic Full-field Optical Coherence Tomography, a Comparison to Conventional Histopathological Findings for the Diagnosis of Either Acute Kidney Injury or Chronic Kidney Disease in Routine Practices (NEPHROCT)
Chronic Kidney DiseasesAcute Kidney InjuryTomography Optical Coherence
Centre Hospitalier William Morey - Chalon sur Saône50 enrolled1 locationNCT05728216
Recruiting
Phase 2
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Centre Hospitalier Universitaire de Besancon105 enrolled14 locationsNCT05528952
Recruiting
Not Applicable
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
Hepatocellular Carcinoma
Centre Hospitalier Universitaire de Besancon120 enrolled10 locationsNCT06796114
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca300 enrolled40 locationsNCT06726720
Recruiting
Phase 3
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
Chronic Kidney Disease(CKD)Uncontrolled Hypertension
University Hospital, Tours720 enrolled40 locationsNCT05732727
Recruiting
Phase 3
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
Anal Cancer
Federation Francophone de Cancerologie Digestive310 enrolled114 locationsNCT06207981
Recruiting
Phase 3
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome824 enrolled64 locationsNCT06918002
Recruiting
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
Multiple Myeloma
Intergroupe Francophone du Myelome180 enrolled20 locationsNCT05208086
Recruiting
Not Applicable
Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)
Chronic Kidney Disease stage4Chronic Kidney Disease Stage 5Chronic Kidney Disease Stage 3B+1 more
Dr. Schär AG / SPA244 enrolled21 locationsNCT05489120
Recruiting
Phase 3
CARE1 Pragmatic Clinical Trial
Metastatic Kidney CancerMetastatic Kidney Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris1,250 enrolled46 locationsNCT06364631
Recruiting
A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort
Malignant Hypertension
Centre Hospitalier de PAU1,200 enrolled37 locationsNCT03755726
Recruiting
Phase 3
Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over
Colonic Adenocarcinoma
Federation Francophone de Cancerologie Digestive774 enrolled140 locationsNCT02355379